GLAXOSMITHKLINE PLC Form 6-K March 02, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 02 March 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards

On 1 March 2018, the Company granted awards to the Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) which was approved by shareholders on 4 May 2017.

Executive Directors are required to defer 50% of any bonus earned into Ordinary Shares or ADSs for a period of three years. Other participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs for the same period.

With effect from 2018, DABP Matching Awards are no longer granted.

The awards of deferred shares (Deferred Bonus Awards) have been granted as conditional awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.

The numbers of shares shown below are exclusive of dividend reinvestment that will accrue during the deferral period.

Transaction notification

1.	. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Ms E Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial Notification	
2.	Details of the issuer, emission allowanc	e market participant, auction	
Ζ.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to l	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction	; (iii) each date; and (iv) each	
	place where transaction(s) has been conducted		
	1	Ordinary shares of 25 pence	
		each ('Ordinary Shares')	
a)	Description of the financial instrument		
	I I I I I I I I I I I I I I I I I I I	ISIN: GB0009252882	
b)	Nature of the transaction	Deferred Bonus Award of	
5)		Ordinary Shares (under the	
		Standy Shares (under the	

	Eugar Film	g. GLANUS	
		GlaxoSmith Deferred Ar Plan).	
		Price(s)	Volume(s)
c	Price(s) and volume(s)	£13.072	58,889
0)	Thee(s) and volume(s)	215.072	50,007
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
e)	Date of the transaction	2018-03-01	
,	Place of the transaction		
f)		n/a	
1. a)	Details of PDMR/person closely associations of PDMR/person closely association and the statement of the stat	ated with the Mr R Conno	
,		President, G	
b)	Position/status		ing & Supply
c)	Initial notification/ amendment	Initial Notif	• • • • •
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	•	icipant, auction
a)	Name	GlaxoSmith	Kline plc
	LEI		TVUYLO1D793
0)	Details of the transaction(s): section to l		
3.	instrument; (ii) each type of transaction place where transaction(s) has been con	; (iii) each da	• •
,		-	ares of 25 pence ary Shares')
a)	Description of the financial instrument	ISIN: GB00	09252882
b)	Nature of the transaction		
c)	Price(s) and volume(s)	Price(s) £13.072	Volume(s) 12,476
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
e)		2018-03-01	
	D1 0.1		

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

b) Position/status President, Global Vaccines

Initial notification/ Initial Notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor GlaxoSmithKline plc a) Name b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Deferred Bonus Award of Ordinary Shares (under the

Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c)	Price(s) and volume(s)	Price(s) £13.072	Volume(s) 18,687
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
e)	Date of the transaction	2018-03-01	
f)	Place of the transaction	n/a	

Details of PDMR/person closely associated with them ('PCA')		
Name	Mr S Dingemans	
Position/status	Chief Financial Officer	
Initial notification/ amendment	Initial Notification	
Details of the issuer, emission allowance	e market participant, auction	
platform, auctioneer or auction monitor		
Name	GlaxoSmithKline plc	
LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section to l	be repeated for (i) each type of	
instrument; (ii) each type of transaction	; (iii) each date; and (iv) each	
place where transaction(s) has been conducted		
Description of the financial instrument	Ordinary shares of 25 pence	
_	each ('Ordinary Shares')	
	Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction place where transaction(s) has been com	

ISIN: GB0009252882

	Deferred Bonus Award of
	Ordinary Shares (under the
	GlaxoSmithKline 2017
b) Nature of the transaction	Deferred Annual Bonus
	Plan).

c)	Price(s) and volume(s)	Price(s) £13.072	Volume(s) 41,674
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
e)	Date of the transaction	2018-03-01	
f)	Place of the transaction	n/a	

1.	Details of PDMR/person	closely associat	ted with them ('PCA')
----	------------------------	------------------	-----------------------

a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics and Compliance
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowanc platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to l	be repeated for (i) each type of
3.	instrument; (ii) each type of transaction	
	place where transaction(s) has been con	
		Ordinary shares of 25 pence each ('Ordinary Shares')
a)	Description of the financial instrument	cuch (Granning Shares)
u)		ISIN: GB0009252882
		Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus

Plan).

- Aggregated information n/a (single transaction) d)
- Aggregated volume Price
- e) Date of the transaction 2018-03-01 Place of the transaction n/a
- f)
- 1. Details of PDMR/person closely associated with them ('PCA')

1.	Details of I Divin/person closely associated with them (I CA)		
a)	Name	Mr L Miels	
h)	Position/status	President, Global	
0)	r osmon/status	Pharmaceuticals	
c)	Initial notification/	Initial Notification	
0)	amendment	Initial Notification	
2.	Details of the issuer, emission allowance	e market participant, auction	
۷.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to l	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction	; (iii) each date; and (iv) each	
	place where transaction(s) has been con	ducted	
		Ordinary shares of 25 pence	
		each ('Ordinary Shares')	
a)	Description of the financial instrument		
		ISIN: GB0009252882	
		Deferred Bonus Award of	
		Ordinary Shares (under the	
		GlaxoSmithKline 2017	
		Deferred Annual Bonus	

Plan).

c) Price(s) and volume(s)	Price(s) £13.072	Volume(s) 11,848
d) Aggregated information Aggregated volume Price	n/a (single	transaction)
e) Date of the transaction	2018-03-01	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

1.	Details of I Divinoperson closely associa	alcu while inchi (TCA)	
a)	Name	Mr B McNamara	
b)	Desition/status	CEO, GSK Consumer	
0)	Position/status	Healthcare	
	Initial notification/	Initial Notification	
c)	amendment	Initial Notification	
h	Details of the issuer, emission allowance	e market participant, auction	
2.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to l	be repeated for (i) each type of	
3.	instrument; (ii) each type of transaction	; (iii) each date; and (iv) each	
	place where transaction(s) has been con	ducted	
		American Depositary Shares	
		('ADSs')	
a)	Description of the financial instrument		
	-	ISIN: US37733W1053	
		Deferred Bonus Award of	

Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

b) Nature of the transaction

c)	Price(s) and volume(s)	Price(s) \$36.31	Volume(s) 6,320
d)	Aggregated information Aggregated volume Price	n/a (single t	transaction)
e)	Date of the transaction	2018-03-01	
f)	Place of the transaction	n/a	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial Notification
~	Details of the issuer, emission allowance market participant, auction	
2.	platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
•		

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

c)	Price(s) and volume(s)	Price(s) £13.072	Volume(s) 12,110
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
e)	Date of the transaction	2018-03-01	
f)	Place of the transaction	n/a	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance	e market participant, auction
Ζ.	platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to b	be repeated for (i) each type of
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each	
	place where transaction(s) has been con	ducted
		Ordinary shares of 25 pence each ('Ordinary Shares')
a)	Description of the financial instrument	-
	-	ISIN: GB0009252882
b)	Nature of the transaction	Deferred Bonus Award of
		Ordinary Shares (under the
		GlaxoSmithKline 2017

Deferred Annual Bonus Plan).

c)	Price(s) and volume(s)	Price(s) £ 13.072	Volume(s) 13,163
d)	Aggregated information Aggregated volume Price	n/a (single tr	ansaction)
e)	Date of the transaction	2018-03-01	
f)	Place of the transaction	n/a	

1.	Details of PDMR/person closely associa	ated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance	e market participant, auction
۷.	platform, auctioneer or auction monitor	
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to l	be repeated for (i) each type of
3.	instrument; (ii) each type of transaction	; (iii) each date; and (iv) each
	place where transaction(s) has been conducted	
		Ordinary shares of 25 pence
		each ('Ordinary Shares')
a)	Description of the financial instrument	-
-	•	ISIN: GB0009252882
		Deferred Bonus Award of
		Ordinary Shares (under the
		GlaxoSmithKline 2017

b) Nature of the transaction

c) I	Price(s)	and	volume(s)	
------	----------	-----	-----------	--

Price(s) Volume(s) £13.072 8,193

Deferred Annual Bonus

Plan).

d) Aggregated information

n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2018-03-01
- Place of the transaction f) n/a

1	Details of PDMR/person closely associa	at a d with them (\mathbf{PCA})
1. a)	Name	Ms K Terrell
/		Chief Digital & Technology
b)	Position/status	Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowanc platform, auctioneer or auction monitor	A A
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to l	be repeated for (i) each type of
3.	3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
		American Depositary Shares ('ADSs')
a)	Description of the financial instrument	
		ISIN: US37733W1053
		Deferred Bonus Award of
		ADSs (under the
		GlaxoSmithKline 2017
		Deferred Annual Bonus
		Plan).
b)	Nature of the transaction	

c) Price(s) and volume(s)	Price(s) Volume(s) \$36.31 2,137
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2018-03-01
f) Place of the transaction	n/a

- 1. Details of PDMR/person closely associated with them ('PCA')
 - Mr D Troy
- SVP & General Counsel b) Position/status Initial Notification
- c) Initial notification/

a) Name

amendment

- 2. Details of the issuer, emission allowance market participant, auction
- ². platform, auctioneer or auction monitor
- a) Name

- GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares ('ADSs')

a) Description of the financial instrument

ISIN: US37733W1053

Deferred Bonus Award of ADSs (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

b) Nature of the transaction

c)	Price(s) and volume(s)	Price(s) \$36.31	Volume(s) 7,349
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
	Date of the transaction	2018-03-01	
f)	Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr P Vallance b) Position/status Outgoing President, R&D Initial notification/ Initial Notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Deferred Bonus Award of Ordinary Shares (under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan).

b) Nature of the transaction

c) Price(s) and volume(s)	Price(s) Volume(s) £13.072 43,111
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2018-03-01
f) Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: March 02, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc